Clinical Trial Search

Primary: Size of Wheal Diameter at Site of Skin Test Application, Measured 15 Minutes After Injection — 3.5 cm

Primary: Detectable Hookworm Infection — 0; 0; 0; 0 Participants

Primary: Duodenal Villus Height:Crypt Depth — 2.73; 2.73 Ratio — p=0.693

Primary: 100 Mcg/ml Na-ASP-2 Prick-puncture Skin Test — 0 Units on a scale

Primary: Cure Rate — 1; 31; 6; 40 Participants

Primary: Cure Rate (CR) of Mebendazole Against Hookworm — 13; 97.9 percentage of participants cured

Primary: Geometric Mean Egg Reduction Rate (ERR) of the Two Formulations of Mebendazole Against Hookworm — 68.5; 70.8 percentage change in hookworm egg counts

Primary: Immediate Vaccine Related Adverse Events — 4; 1; 0; 1 Participants

Primary: Cure Rate Against T. Trichiura and Hookworm Infections — 4; 2; 4; 5 Participants

Primary: Vaccine-related Adverse Events — 1; 3; 0; 3 Participants

Primary: Vaccine-Related Adverse Events — 8; 8; 8; 8 Participants

Primary: Comparison of Arms - Benin — 322; 748; 11; 11 Participants

Primary: Microfilarial Counts at 1 Year — 0; 0; 0 MF/ML — p=<0.2

Primary: Cure Rate — 16.3; 28.3; 18.8 percentage of participants

Primary: Number of Participants T. Trichiura Egg Negative Post-Treatment (Cured) — 24; 32; 16; 140 Participants

Primary: Cure Rate (CR) of Moxidectin/Albendazole Combination Therapy Compared to Albendazole Monotherapy Against T. Trichiura — 15.3; 13.4 percentage of participants (%)

Primary: Number of Participants With and Without Intestinal Parasitic Infection — 36; 84 Participants

Primary: Egg Reduction Rate Against T. Trichiura — 96.8; 99.0; 86.2; 94.2 Percent change

Primary: Mean Newborn Birth Weight — 2.85; 2.85 kilograms — p=0.988

Primary: Cure Rate for Ascaris Lumbricoides at the End of Double-blind Treatment Period — 11.1; 83.7 percentage of participants — p=< 0.001